SANF Share Price

Open 81.45 Change Price %
High 81.65 1 Day -0.40 -0.49
Low 80.85 1 Week 0.00 0.00
Close 80.85 1 Month -3.80 -4.49
Volume 709 1 Year 4.80 6.31
52 Week High 92.70
52 Week Low 73.60
SANF Important Levels
Resistance 2 81.59
Resistance 1 81.29
Pivot 81.12
Support 1 80.41
Support 2 80.11
BIT Italy Most Active Stocks
RN 0.04 0.00%
RN 0.04 0.00%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.75 1.35%
ISP 2.89 0.00%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
AE 0.50 8.70%
AE 0.50 8.70%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
More..
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
FTL 3.65 -7.36%
TBS 1.64 -6.82%
STEF 0.19 -5.00%
POPR 0.59 -4.84%
BIM 0.65 -4.41%
BIM 0.65 -4.41%
ZUCR 0.24 -4.00%
S24 1.70 -3.95%
More..

Sanofi (BIT: SANF)

SANF Technical Analysis 4
As on 1st Nov 2017 SANF Share Price closed @ 80.85 and we RECOMMEND Sell for LONG-TERM with Stoploss of 82.45 & Strong Sell for SHORT-TERM with Stoploss of 83.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
SANF Target for December
1st Target up-side 83.98
2nd Target up-side 85.97
3rd Target up-side 87.96
1st Target down-side 78.32
2nd Target down-side 76.33
3rd Target down-side 74.34
SANF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sanofi-aventis.com
SANF Address
SANF
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
SANF Latest News
Interactive Technical Analysis Chart Sanofi ( SANF BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SANF Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.